Logo image
Back
A systematic review supporting the Society for Vascular Surgery guideline update on the management of intermittent claudication
Journal article   Peer reviewed

A systematic review supporting the Society for Vascular Surgery guideline update on the management of intermittent claudication

Samer Saadi, Tarek Nayfeh, Rami Rajjoub, Bashar Hasan, Mohammed Firwana, Tabinda Jawaid, Walid Hazem, Sahrish Shah, Yahya Alsawaf, Mohamed O. Seisa, …
Journal of vascular surgery, Vol.82(2), pp.688-697
08/01/2025
DOI: 10.1016/j.jvs.2024.12.135
PMID: 40316186

View Online

Abstract

Objective: This systematic review and meta-analysis evaluates the current evidence on the management of intermittent claudication (IC), a prevalent manifestation of peripheral arterial disease (PAD). Methods: We conducted comprehensive searches of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus. We addressed six questions developed by a guideline committee from the Society for Vascular Surgery, addressing pharmacological treatments, exercise regimens, endovascular interventions, and predictors of major adverse cardiovascular, limb-related events, and mortality. Results: The search resulted in 5333 citations, from which we included 73 studies (46 randomized trials). In patients with PAD and IC who had one or more high-risk comorbidities, low-dose rivaroxaban and aspirin were associated with lower risk of major adverse limb events and major adverse cardiovascular events than aspirin alone. In patients who have undergone surgical or endovascular interventions for PAD, the addition of low-dose rivaroxaban to aspirin may improve limb outcomes. Of note, rivaroxaban trials excluded patients at high risk of bleeding. Single antiplatelet agents showed no significant efficacy differences head-to-head in ambulatory patients with IC and had a lower bleeding risk compared with combination therapy or anticoagulation. Home exercise programs were feasible and may be an alternative to supervised exercise in ambulatory patients with IC and in those who had revascularization. Several comorbidities increased the risk of adverse outcomes after revascularization for IC, such as advanced age, diabetes, coronary artery disease, chronic obstructive pulmonary disease, previous interventions, congestive heart failure, infrapopliteal artery involvement, and longer lesion lengths. In patients with IC undergoing endovascular intervention for superficial femoral artery disease, plain balloon angioplasty was associated with worse outcomes than drug elution or stent implantation for intermediate or longer lesions (ie, >5 cm). Conclusions: This systematic review summarizes the current evidence base for the management of IC, offering insights into the relative benefits and risks of various therapeutic strategies. The findings underscore the need for individualized patient care, considering both the potential benefits and risks associated with different interventions.
 Anticoagulation therapy Antiplatelet therapy Endovascular surgery Exercise therapy Intermittent claudication Meta-analysis Open surgery Peripheral artery disease Pharmacological management Revascularization Systematic review

Details

Metrics

2 Record Views
2 Times Cited - Web of Science
Logo image